Zymeworks receives FDA clearance for IND application of ZW171, a 2+1 T-cell targeting bispecific antibody for mesothelin-expressing cancers.
Zymeworks announces FDA clearance of IND application for ZW171, a 2+1 T-cell targeting bispecific antibody for mesothelin-expressing cancers. The company intends to submit applications to other regulatory bodies for authorization to conduct clinical trials in the second half of 2024. ZW171 is designed to facilitate T cell-mediated tumor cell destruction and has shown promising preclinical results.
June 17, 2024
5 Articles